A drug designed to help patients with multiple sclerosis (MS) failed to hit several targets in a late-stage trial.
Adamas Pharmaceuticals tested how well different doses of the medication, Gocovri, helped MS patients walk. Although a higher dose of the treatment improved walking speed compared to a placebo, it failed to help with the trial’s secondary walking goals.
Gocovri has already been approved to treat side-effects associated with a Parkinson’s drug. The news that it didn’t perform as well as the company had hoped for in the MS trial sent shares for Adamas plummeting by 45 percent. The company said it will now assess its continued investment in Gocovri as an MS treatment.
Read the Reuters report.
